{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:27Z","timestamp":1782417507822,"version":"3.54.5"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06669-6","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:26:44Z","timestamp":1766564804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["New advances in treating late-onset Pompe Disease: A narrative review"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3681-1820","authenticated-orcid":false,"given":"Misha","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8593-8463","authenticated-orcid":false,"given":"Zainab","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3539-246X","authenticated-orcid":false,"given":"Eesha Asghar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1431-0889","authenticated-orcid":false,"given":"Mufliha","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5950-3310","authenticated-orcid":false,"given":"Farhana","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6346-6629","authenticated-orcid":false,"given":"Eeshal","family":"Zulfiqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8298-3495","authenticated-orcid":false,"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Mahmood","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-6372","authenticated-orcid":false,"given":"Samar A.","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"3","key":"6669_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ana.410380316","volume":"38","author":"JHJ Wokke","year":"1995","unstructured":"Wokke JHJ, Ausems MGEM, Van Den Boogaard MH, Ippel EF, Van Diggelen O, Kroos MA, Boer M, Jennekens FGI, Reuser AJJ, Van Amstel HKP (1995) Genotype\u2010phenotype correlation in adult\u2010onset acid maltase deficiency. Ann Neurol 38(3):450\u2013454. https:\/\/doi.org\/10.1002\/ana.410380316","journal-title":"Ann Neurol"},{"issue":"4","key":"6669_CR2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","volume":"15","author":"L Kohler","year":"2018","unstructured":"Kohler L, Puertollano R, Raben N (2018) Pompe disease: from basic science to therapy. Neurotherapeutics 15(4):928\u2013942. https:\/\/doi.org\/10.1007\/s13311-018-0655-y","journal-title":"Neurotherapeutics"},{"issue":"s1","key":"6669_CR3","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1017\/cjn.2024.170","volume":"51","author":"A Opala","year":"2024","unstructured":"Opala A (2024) P.064 a case of late onset Pompe disease presenting in 6th decade. Can J Neurol Sci 51(s1):S33","journal-title":"Can J Neurol Sci"},{"key":"6669_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neuroscience.2024.09.043","volume":"563","author":"W Kong","year":"2024","unstructured":"Kong W, Lu C, Wang L (2024) Global birth prevalence of Pompe disease: a systematic review and meta-analysis. Neuroscience 563:167\u2013174. https:\/\/doi.org\/10.1016\/j.neuroscience.2024.09.043","journal-title":"Neuroscience"},{"issue":"2","key":"6669_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ymgme.2013.03.016","volume":"109","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, De Vries JM, Brusse E, Kruijshaar ME, Hop WC, Murawska M, Van Den Berg LE, Reuser AJ, Van Doorn PA, Hagemans ML, Plug I, Van Der Ploeg AT (2013) Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab 109(2):174\u2013178. https:\/\/doi.org\/10.1016\/j.ymgme.2013.03.016","journal-title":"Mol Genet Metab"},{"issue":"4","key":"6669_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ymgme.2013.05.021","volume":"109","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Schober A, Kruijshaar M, Plug I, Karabul N, Deschauer M, Van Doorn P, Van Der Ploeg A, Schoser B, Hanisch F (2013) Pain in adult patients with Pompe disease. Mol Genet Metab 109(4):371\u2013376. https:\/\/doi.org\/10.1016\/j.ymgme.2013.05.021","journal-title":"Mol Genet Metab"},{"issue":"3","key":"6669_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","volume":"120","author":"J Chan","year":"2017","unstructured":"Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, Case LE, Jones HN, Kishnani PS (2017) The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab 120(3):163\u2013172. https:\/\/doi.org\/10.1016\/j.ymgme.2016.12.004","journal-title":"Mol Genet Metab"},{"issue":"4","key":"6669_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2016","unstructured":"Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A (2016) Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol 264(4):621\u2013630. https:\/\/doi.org\/10.1007\/s00415-016-8219-8","journal-title":"J Neurol"},{"issue":"1-2","key":"6669_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neurol.2022.12.004","volume":"179","author":"C Gu\u00e9my","year":"2023","unstructured":"Gu\u00e9my C, Lafor\u00eat P (2023) The new horizons for treatment of Late-Onset Pompe Disease (LOPD). Rev Neurol (Paris) 179(1\u20132):81\u201389. https:\/\/doi.org\/10.1016\/j.neurol.2022.12.004","journal-title":"Rev Neurol (Paris)"},{"key":"6669_CR10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s Disease. N Engl J Med 362:1396\u20131406","journal-title":"N Engl J Med"},{"key":"6669_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2009","unstructured":"Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S et al (2009) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91\u201397","journal-title":"J Neurol"},{"key":"6669_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/jgm.1511","volume":"12","author":"B Sun","year":"2010","unstructured":"Sun B, Li S, Bird A, Yi H, Kemper A, Thurberg BL, Koeberl DD (2010) Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe Diseasee. J Gene Med 12:881\u2013891","journal-title":"J Gene Med"},{"key":"6669_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"LDM Pena","year":"2019","unstructured":"Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Lafor\u00eat P, Mengel KE, Pestronk A, Pouget J et al (2019) Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe Disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul Disord 29:167\u2013186","journal-title":"Neuromuscul Disord"},{"key":"6669_CR14","doi-asserted-by":"crossref","unstructured":"Dhillon S. Avalglucosidase alfa: First Approval. Drugs [Internet]. 2021 Oct 30;81(15):1803\u20139. Available from: https:\/\/link.springer.com\/10.1007\/s40265-021-01600-3","DOI":"10.1007\/s40265-021-01600-3"},{"key":"6669_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2019.11.107","volume":"129","author":"MM Dimachkie","year":"2020","unstructured":"Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, Kishnani PS, Ladha S, Lafor\u00eat P, Mengel KE, Pena LD, Sacconi S et al (2020) NEO1 and NEO-EXT studies: long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 5.5 years in late-onset Pompe disease patients. Mol Genet Metab 129:S49","journal-title":"Mol Genet Metab"},{"issue":"1","key":"6669_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0693-2","volume":"12","author":"BJ Byrne","year":"2017","unstructured":"Byrne BJ, Geberhiwot T, Barshop BA, Barohn R, Hughes D, Bratkovic D, Desnuelle C, Laforet P, Mengel E, Roberts M, Haroldsen P, Reilley K, Jayaram K, Yang K, Walsh L, POM-001\/002 Investigators (2017) A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease. Orphanet J Rare Dis 12(1):144. https:\/\/doi.org\/10.1186\/s13023-017-0693-2","journal-title":"Orphanet J Rare Dis"},{"key":"6669_CR17","doi-asserted-by":"crossref","unstructured":"Holt BD, Elliott SJ, Meyer R, Reyes D, O\u2019Neil K, Druzina Z, et al. A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease. Mol Ther [Internet]. 2025 Jan;33(1):235\u201348. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624007603","DOI":"10.1016\/j.ymthe.2024.11.033"},{"key":"6669_CR18","doi-asserted-by":"crossref","unstructured":"Byrne BJ, Parenti G, Schoser B, van der Ploeg AT, Do H, Fox B, et al. Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease. Front Neurol [Internet]. 2024 Oct 18;15. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1451512\/full","DOI":"10.3389\/fneur.2024.1451512"},{"key":"6669_CR19","doi-asserted-by":"crossref","unstructured":"Blair HA. Cipaglucosidase Alfa: First Approval. Drugs [Internet]. 2023 Jun 15;83(8):739\u201345. Available from: https:\/\/link.springer.com\/10.1007\/s40265-023-01886-5","DOI":"10.1007\/s40265-023-01886-5"},{"issue":"10","key":"6669_CR20","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0045","volume":"13","author":"S Shohet","year":"2024","unstructured":"Shohet S, Hummel N, Fu S et al (2024) Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. J Comp Eff Res 13(10):e240045. https:\/\/doi.org\/10.57264\/cer-2024-0045","journal-title":"J Comp Eff Res"},{"issue":"12","key":"6669_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Lafor\u00eat P, Toscano A, Castelli J, D\u00edaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS, PROPEL Study Group (2021) Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol 20(12):1027\u20131037. https:\/\/doi.org\/10.1016\/S1474-4422(21)00331-8","journal-title":"Lancet Neurol"},{"issue":"9","key":"6669_CR22","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","volume":"26","author":"DD Koeberl","year":"2018","unstructured":"Koeberl DD, Case LE, Smith EC, Walters C, Han SO, Li Y, Chen W, Hornik CP, Huffman KM, Kraus WE, Thurberg BL, Corcoran DL, Bali D, Bursac N, Kishnani PS (2018) Correction of biochemical abnormalities and improved muscle function in a phase I\/II clinical trial of clenbuterol in Pompe Disease. Mol Ther 26(9):2304\u20132314. https:\/\/doi.org\/10.1016\/j.ymthe.2018.06.023","journal-title":"Mol Ther"},{"issue":"1-2","key":"6669_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","volume":"119","author":"A van der Ploeg","year":"2016","unstructured":"van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, Pestronk A, Barohn RJ, Dimachkie MM, Goker-Alpan O, Mozaffar T, Pena LD, Simmons Z, Straub V, Guglieri M, Young P, Boentert M, Baudin PY, Wens S, Shafi R, Thurberg BL (2016) Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY study. Mol Genet Metab 119(1\u20132):115\u2013123. https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.013","journal-title":"Mol Genet Metab"},{"key":"6669_CR24","doi-asserted-by":"publisher","first-page":"1336599","DOI":"10.3389\/fimmu.2024.1336599","volume":"15","author":"HA Chen","year":"2024","unstructured":"Chen HA, Hsu RH, Fang CY, Desai AK, Lee NC, Hwu WL, Tsai FJ, Kishnani PS, Chien YH (2024) Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy. Front Immunol 15:1336599. https:\/\/doi.org\/10.3389\/fimmu.2024.1336599","journal-title":"Front Immunol"},{"issue":"5","key":"6669_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/J.YMTHE.2017.02.017","volume":"25","author":"P Kishnani","year":"2017","unstructured":"Kishnani P, Tarnopolsky M, Roberts M et al (2017) Duvoglustat HCl increases systemic and tissue exposure of active acid \u03b1-glucosidase in Pompe patients co-administered with Alglucosidase \u03b1. Mol Ther 25(5):1199\u20131208. https:\/\/doi.org\/10.1016\/J.YMTHE.2017.02.017","journal-title":"Mol Ther"},{"issue":"1","key":"6669_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/J.YMGME.2006.09.010","volume":"90","author":"T Okumiya","year":"2007","unstructured":"Okumiya T, Kroos MA, Vliet L Van, Takeuchi H, Van der Ploeg AT, Reuser AJJ (2007) Chemical chaperones improve transport and enhance stability of mutant \u03b1-glucosidases in glycogen storage disease type II. Mol Genet Metab 90(1):49\u201357. https:\/\/doi.org\/10.1016\/J.YMGME.2006.09.010","journal-title":"Mol Genet Metab"},{"issue":"2","key":"6669_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines1002030","volume":"10","author":"Z Unnisa","year":"2022","unstructured":"Unnisa Z, Yoon JK, Schindler JW, Mason C, Van Til NP (2022) Gene therapy developments for Pompe disease. Biomedicines 10(2):302. https:\/\/doi.org\/10.3390\/biomedicines1002030","journal-title":"Biomedicines"},{"key":"6669_CR28","unstructured":"A gene transfer study for late-onset Pompe disease (RESOLUTE). ClinicalTrials.gov. Identifier: NCT04093349. Last updated November 27, 2024. Last accessed on March 5, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04093349#study-plan"},{"issue":"5","key":"6669_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1089\/hum.2011.063","volume":"23","author":"P Zhang","year":"2012","unstructured":"Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X et al (2012) Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease. Hum Gene Ther 23(5):460\u201372. https:\/\/doi.org\/10.1089\/hum.2011.063","journal-title":"Hum Gene Ther"},{"issue":"6","key":"6669_CR30","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1089\/HUM.2012.250","volume":"24","author":"BK Smith","year":"2013","unstructured":"Smith BK, Collins SW, Conlon TJ et al (2013) Phase I\/II trial of adeno-associated virus\u2013mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe Disease: initial safety and ventilatory outcomes. Hum Gene Ther 24(6):630\u2013640. https:\/\/doi.org\/10.1089\/HUM.2012.250","journal-title":"Hum Gene Ther"},{"key":"6669_CR31","doi-asserted-by":"publisher","unstructured":"Koeberl DD, Kishnani PS, Chen YT. Glycogen storage disease types I and II: treatment updates. J Inherit Metab Dis [Internet]. 2007 Apr 16;30(2):159\u201364. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1007\/s10545-007-0519-9","DOI":"10.1007\/s10545-007-0519-9"},{"key":"6669_CR32","doi-asserted-by":"crossref","unstructured":"Ullman JC, Dick RA, Linzner D, Minga T, Tep S, Satterfield TF, et al. First\u2010in\u2010human evaluation of safety, pharmacokinetics and muscle glycogen lowering of a novel glycogen synthase 1 inhibitor for the treatment of Pompe disease. Clin Pharmacol Ther [Internet]. 2024 Dec 22;116(6):1580\u201392. Available from:","DOI":"10.1002\/cpt.3470"},{"key":"6669_CR33","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","volume":"15","author":"L Kohler","year":"2018","unstructured":"Kohler L, Puertollano R, Raben N (2018) Pompe disease: from basic science to therapy. Neurotherapeutics 15:928\u2013942","journal-title":"Neurotherapeutics"},{"key":"6669_CR34","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","volume":"268","author":"HA Wisselaar","year":"1993","unstructured":"Wisselaar HA, Kroos MA, Hermans MP, Van Beeumens J, Reusers AJ (1993) Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 268:2223\u20132231","journal-title":"J Biol Chem"},{"key":"6669_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1756285613487570","volume":"6","author":"C Angelini","year":"2013","unstructured":"Angelini C, Nascimbeni AC, Semplicini C (2013) Therapeutic advances in the management of Pompe disease and other metabolic myopathies. Ther Adv Neurol Disord 6:311\u2013321","journal-title":"Ther Adv Neurol Disord"},{"key":"6669_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","volume":"117","author":"KM Stepien","year":"2016","unstructured":"Stepien KM, Hendriksz CJ, Roberts M, Sharma R (2016) Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years. Mol Genet Metab 117:413\u2013418","journal-title":"Mol Genet Metab"},{"key":"6669_CR37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2011","unstructured":"Angelini C, The Italian GSDII Group, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E et al (2011) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259:952\u2013958","journal-title":"J Neurol"},{"key":"6669_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM De Vries","year":"2012","unstructured":"De Vries JM, Van der Beek NA, Hop WC, Karstens FP, Wokke JH, De Visser M, Van Engelen BG, Kuks JB, Van der Kooi AJ, Notermans NC et al (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe Disease: an open-label single-center study. Orphanet J Rare Dis 7:73","journal-title":"Orphanet J Rare Dis"},{"key":"6669_CR39","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus E, Kruijshaar ME, Wens SCA, De Vries JM, Favejee MM, Van der Meijden JC, Brusse E, Van Doorn PA, Van der Ploeg AT, Van der Beek NAME (2017) Long-term benefit of enzyme replacement therapy in Pompe Disease: a 5-year prospective study. Neurology 89:2365\u20132373","journal-title":"Neurology"},{"key":"6669_CR40","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel J-Y, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N, Canal A, Brusse E, van Doorn PA, van der Ploeg AT et al (2019) Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology 93:e1756\u2013e1767","journal-title":"Neurology"},{"key":"6669_CR41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, Lafor\u00eat P, Angelini C, Lachmann RH, Pascual SIP, Roberts M, R\u00f6sler K, Stulnig T et al (2017) European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol 24:768-e31","journal-title":"Eur J Neurol"},{"key":"6669_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/nan.12414","volume":"44","author":"M Ripolone","year":"2017","unstructured":"Ripolone M, Violano R, Ronchi D, Mondello S, Nascimbeni A, Colombo I, Fagiolari G, Bordoni A, Fortunato F, Lucchini V et al (2017) Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Neuropathol Appl Neurobiol 44:449\u2013462","journal-title":"Neuropathol Appl Neurobiol"},{"key":"6669_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26\u201333","journal-title":"Mol Genet Metab"},{"key":"6669_CR44","volume":"3","author":"PA Doerfler","year":"2016","unstructured":"Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ (2016) Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther 3:15053","journal-title":"Mol Ther"},{"key":"6669_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jpeds.2017.11.046","volume":"195","author":"E Poelman","year":"2018","unstructured":"Poelman E, Hoogeveen-westerveld M, de Kroos- Haan MA, den Van Hout JMP, Bronsema KJ, de Van Merbel NC, der Van Ploeg AT, Pijnappel WWMP (2018) High sustained antibody titers in patients with classic infantile Pompe Disease following immunomodulation at start of rnzyme replacement therapy. J Pediatr 195:236-243.e3","journal-title":"J Pediatr"},{"key":"6669_CR46","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.4081\/ejtm.2021.9798","volume":"31","author":"C Angelini","year":"2021","unstructured":"Angelini C (2021) Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium. Eur J Transl Myol 31:9798","journal-title":"Eur J Transl Myol"},{"key":"6669_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-020-01416-6","volume":"15","author":"A Sechi","year":"2020","unstructured":"Sechi A, Zuccarelli L, Grassi B, Frangiamore R, De Amicis R, Marzorati M, Porcelli S, Tullio A, Bacco A, Bertoli S et al (2020) Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study. Orphanet J Rare Dis 15:143","journal-title":"Orphanet J Rare Dis"},{"key":"6669_CR48","doi-asserted-by":"crossref","unstructured":"Scheffers, L.E.; Somers, O.C.; Dulfer, K.; Dieleman, G.C.; Walet, S.; Van der Giessen, L.J.; Van der Ploeg, A.T.; Van den Hout, J.M.P.; Van den Berg, L.E.; exercise team. Physical training and high-protein diet improved muscle strength, parent-reported fatigue, and physical quality of life in children with Pompe Diseasee. J. Inherit. Metab. Dis. 2023, 46, 605\u2013617.","DOI":"10.1002\/jimd.12607"},{"key":"6669_CR49","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR et al (2021) Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol 20:1012\u20131026","journal-title":"Lancet Neurol"},{"key":"6669_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.10.010","volume":"25","author":"PS Kishnani","year":"2022","unstructured":"Kishnani PS, Kronn D, Brassier A, Broomfield A, Davison J, Hahn SH, Kumada S, Labarthe F, Ohki H, Pichard S et al (2022) Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report. Genet Med 25:100328","journal-title":"Genet Med"},{"issue":"12","key":"6669_CR51","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, COMET Investigator Group (2021) Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol 20(12):1012\u20131026. https:\/\/doi.org\/10.1016\/S1474-4422(21)00241-6","journal-title":"Lancet Neurol"},{"issue":"2","key":"6669_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.108121","volume":"141","author":"A Toscano","year":"2024","unstructured":"Toscano A, Pollissard L, Msihid J, van der Beek N, Kishnani PS, Dimachkie MM, Berger KI, DasMahapatra P, Thibault N, Hamed A, Zhou T, Haack KA, Schoser B (2024) Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-na\u00efve adults with late-onset Pompe disease compared with alglucosidase alfa: meaningful change analyses from the Phase 3 COMET trial. Mol Genet Metab 141(2):108121. https:\/\/doi.org\/10.1016\/j.ymgme.2023.108121","journal-title":"Mol Genet Metab"},{"issue":"3","key":"6669_CR53","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, Kishnani PS, Lafor\u00eat P, Morgan C, Nations S, Pestronk A, Plotkin H, Rosenbloom BE, Sims KB, Tsao E (2012) Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 107(3):456\u2013461. https:\/\/doi.org\/10.1016\/j.ymgme.2012.09.015","journal-title":"Mol Genet Metab"},{"issue":"7","key":"6669_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/GIM.0b013e3182142966","volume":"13","author":"D Forsha","year":"2011","unstructured":"Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK, Late-Onset Treatment Study Investigators (2011) Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med 13(7):625\u2013631. https:\/\/doi.org\/10.1097\/GIM.0b013e3182142966","journal-title":"Genet Med"},{"issue":"3","key":"6669_CR55","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1017\/S1047951121002079","volume":"32","author":"Byrne, B. J., Colan, S. D., Kishnani, P. S., Foster, M. C., Sparks, S. E., Gibson, J. B., An Haack, K., Stockton, D. W., Pe\u00f1a, L. D. M., Hahn, S. H., Johnson, J., Tanpaiboon, P. X., Leslie, N. D., Kronn, D., Hillman, R. E., Wang, R. Y., & Pompe ADVANCE Study Consortium","year":"2022","unstructured":"Byrne, B. J., Colan, S. D., Kishnani, P. S., Foster, M. C., Sparks, S. E., Gibson, J. B., An Haack, K., Stockton, D. W., Pe\u00f1a, L. D. M., Hahn, S. H., Johnson, J., Tanpaiboon, P. X., Leslie, N. D., Kronn, D., Hillman, R. E., Wang, R. Y., & Pompe ADVANCE Study Consortium (2022) Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort. Cardiol Young 32(3):364\u2013373. https:\/\/doi.org\/10.1017\/S1047951121002079","journal-title":"Cardiol Young"},{"issue":"5","key":"6669_CR56","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00408-013-9489-x","volume":"191","author":"A Vianello","year":"2013","unstructured":"Vianello A, Semplicini C, Paladini L, Concas A, Ravaglia S, Servidei S, Toscano A, Mongini T, Angelini C, Pegoraro E (2013) Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. Lung 191(5):537\u2013544. https:\/\/doi.org\/10.1007\/s00408-013-9489-x","journal-title":"Lung"},{"issue":"1","key":"6669_CR57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-020-01416-6","volume":"15","author":"A Sechi","year":"2020","unstructured":"Sechi A, Zuccarelli L, Grassi B, Frangiamore R, De Amicis R, Marzorati M, Porcelli S, Tullio A, Bacco A, Bertoli S, Dardis A, Biasutti L, Pasanisi MB, Devigili G, Bembi B (2020) Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study. Orphanet J Rare Dis 15(1):143. https:\/\/doi.org\/10.1186\/s13023-020-01416-6","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"6669_CR58","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10545-010-9204-5","volume":"33","author":"S Ravaglia","year":"2010","unstructured":"Ravaglia S, Pichiecchio A, Ponzio M, Danesino C, Saeidi Garaghani K, Poloni GU, Toscano A, Moglia A, Carlucci A, Bini P, Ceroni M, Bastianello S (2010) Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. J Inherit Metab Dis 33(6):737\u2013745. https:\/\/doi.org\/10.1007\/s10545-010-9204-5","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"6669_CR59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","volume":"33","author":"B Bembi","year":"2010","unstructured":"Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, Rigoldi M, Moglia A, Costa A, Carlucci A, Danesino C, Pittis MG, Dardis A, Ravaglia S (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33(6):727\u2013735. https:\/\/doi.org\/10.1007\/s10545-010-9201-8","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"6669_CR60","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1007\/s00415-024-12236-0","volume":"271","author":"Schoser, B., Kishnani, P. S., Bratkovic, D., Byrne, B. J., Claeys, K. G., D\u00edaz-Manera, J., Lafor\u00eat, P., Roberts, M., Toscano, A., van der Ploeg, A. T., Castelli, J., Goldman, M., Holdbrook, F., Sitaraman Das, S., Wasfi, Y., Mozaffar, T., & ATB200-07 Study Group","year":"2024","unstructured":"Schoser, B., Kishnani, P. S., Bratkovic, D., Byrne, B. J., Claeys, K. G., D\u00edaz-Manera, J., Lafor\u00eat, P., Roberts, M., Toscano, A., van der Ploeg, A. T., Castelli, J., Goldman, M., Holdbrook, F., Sitaraman Das, S., Wasfi, Y., Mozaffar, T., & ATB200-07 Study Group (2024) 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07). J Neurol 271(5):2810\u20132823. https:\/\/doi.org\/10.1007\/s00415-024-12236-0","journal-title":"J Neurol"},{"issue":"12","key":"6669_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012993.pub2","volume":"12","author":"S Dalmia","year":"2023","unstructured":"Dalmia S, Sharma R, Ramaswami U, Hughes D, Jahnke N, Cole D, Smith S, Remmington T (2023) Enzyme replacement therapy for late-onset Pompe disease. Cochrane Database Syst Rev 12(12):CD012993. https:\/\/doi.org\/10.1002\/14651858.CD012993.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"6669_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16383","volume":"31","author":"B Schoser","year":"2024","unstructured":"Schoser B, van der Beek NAME, Broomfield A et al (2024) Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. Eur J Neurol 31(9):e16383. https:\/\/doi.org\/10.1111\/ene.16383","journal-title":"Eur J Neurol"},{"issue":"1","key":"6669_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.36185\/2532-1900-1106","volume":"44","author":"B Risi","year":"2025","unstructured":"Risi B, Caria F, Bertella E, Giovanelli G (2025) Management of Pompe disease alongside and beyond ERT: a narrative review. Acta Myol 44(1):11\u201322. https:\/\/doi.org\/10.36185\/2532-1900-1106","journal-title":"Acta Myol"},{"issue":"7","key":"6669_CR64","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/MT.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ (2015) Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther 23(7):1138. https:\/\/doi.org\/10.1038\/MT.2015.62","journal-title":"Mol Ther"},{"issue":"6","key":"6669_CR65","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/MT.2009.53","volume":"17","author":"C Porto","year":"2009","unstructured":"Porto C, Cardone M, Fontana F et al (2009) The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe Disease fibroblasts. Mol Ther 17(6):964. https:\/\/doi.org\/10.1038\/MT.2009.53","journal-title":"Mol Ther"},{"issue":"23","key":"6669_CR66","doi-asserted-by":"publisher","first-page":"9462","DOI":"10.1021\/ACS.JMEDCHEM.7B00646","volume":"60","author":"D D\u2019Alonzo","year":"2017","unstructured":"D\u2019Alonzo D, De Fenza M, Porto C et al (2017) N-Butyl-l-deoxynojirimycin (l-NBDNJ): synthesis of an allosteric enhancer of \u03b1-glucosidase activity for the treatment of Pompe Disease. J Med Chem 60(23):9462\u20139469. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.7B00646","journal-title":"J Med Chem"},{"issue":"3","key":"6669_CR67","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/sj.mt.6300074","volume":"15","author":"G Parenti","year":"2007","unstructured":"Parenti G, Zuppaldi A, Gabriela Pittis M et al (2007) Pharmacological enhancement of mutated \u03b1-glucosidase activity in fibroblasts from patients with Pompe Disease. Mol Ther 15(3):508\u2013514. https:\/\/doi.org\/10.1038\/sj.mt.6300074","journal-title":"Mol Ther"},{"issue":"11","key":"6669_CR68","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/MT.2014.138","volume":"22","author":"G Parenti","year":"2014","unstructured":"Parenti G, Fecarotta S, La Marca G et al (2014) A chaperone enhances blood \u03b1-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy. Mol Ther 22(11):2004\u20132012. https:\/\/doi.org\/10.1038\/MT.2014.138","journal-title":"Mol Ther"},{"key":"6669_CR69","unstructured":"Amicus Therapeutics Announces European Commission approval for PombilitiTM in patients with late-onset Pompe Disease | Amicus Therapeutics. Accessed February 18, 2025. https:\/\/ir.amicusrx.com\/news-releases\/news-release-details\/amicus-therapeutics-announces-european-commission-approval-1"},{"issue":"5","key":"6669_CR70","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.hoc.2017.06.007","volume":"31","author":"T Athanasopoulos","year":"2017","unstructured":"Athanasopoulos T, Munye MM, Y\u00e1\u00f1ez-Mu\u00f1oz RJ (2017) Nonintegrating gene therapy vectors. Hematol Oncol Clin North Am 31(5):753\u2013770","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"6669_CR71","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1089\/HUMC.2017.146","volume":"28","author":"M Corti","year":"2017","unstructured":"Corti M, Liberati C, Smith BK et al (2017) Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease. Hum Gene Ther Clin Dev 28(4):208\u2013218. https:\/\/doi.org\/10.1089\/HUMC.2017.146","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"5","key":"6669_CR72","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","volume":"12","author":"LM Franco","year":"2005","unstructured":"Franco LM, Sun B, Yang X, Bird A, Zhang H, Schneider A et al (2005) Evasion of immune responses to introduced human acid \u0391-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 12(5):876\u201384. https:\/\/doi.org\/10.1016\/j.ymthe.2005.04.024","journal-title":"Mol Ther"},{"issue":"8","key":"6669_CR73","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/mt.2008.133","volume":"16","author":"B Sun","year":"2008","unstructured":"Sun B, Young SP, Li P, Di C, Brown T, Salva MZ et al (2008) Correction of multiple striated muscles in murine pompe disease through adeno-associated virus\u2013mediated gene therapy. Mol Ther 16(8):1366\u201371. https:\/\/doi.org\/10.1038\/mt.2008.133","journal-title":"Mol Ther"},{"issue":"7","key":"6669_CR74","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","volume":"31","author":"EC Smith","year":"2023","unstructured":"Smith EC, Hopkins S, Case LE, Xu M, Walters C, Dearmey S et al (2023) Phase I study of liver depot gene therapy in late-onset Pompe disease. Mol Ther 31(7):1994\u20132004. https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.014","journal-title":"Mol Ther"},{"key":"6669_CR75","unstructured":"AAV2\/8-LSPHGAA (ACTUS-101) in late-onset Pompe Disease. ClinicalTrials.gov. Identifier: NCT03533673. Last updated June 6,2023. Last accessed on March 5, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03533673"},{"key":"6669_CR76","unstructured":"Gene transfer study in patients with late onset Pompe Disease. ClinicalTrials.gov. Identifier: NCT04174105, Last updated Novmber 18, 2024. Last accesed on March 5, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04174105"},{"issue":"10","key":"6669_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/MTNA.2014.57","volume":"3","author":"NP Clayton","year":"2014","unstructured":"Clayton NP, Nelson CA, Weeden T et al (2014) Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe Disease. Mol Ther Nucleic Acids 3(10):e206. https:\/\/doi.org\/10.1038\/MTNA.2014.57","journal-title":"Mol Ther Nucleic Acids"},{"key":"6669_CR78","doi-asserted-by":"publisher","unstructured":"Douillard-Guilloux G, Raben N, Takikita S, Ferry A, Vignaud A, Guillet-Deniau I, et al. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum Mol Genet [Internet]. 2010 Feb 15;19(4):684\u201396. Available from: https:\/\/academic.oup.com\/hmg\/article-lookup\/doi\/https:\/\/doi.org\/10.1093\/hmg\/ddp535","DOI":"10.1093\/hmg\/ddp535"},{"key":"6669_CR79","doi-asserted-by":"crossref","unstructured":"Colpaert M, Singh PK, Donohue KJ, Pires NT, Fuller DD, Corti M, et al. Neurological glycogen storage diseases and emerging therapeutics. Neurotherapeutics [Internet]. 2024 Sep;21(5):e00446. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924001338","DOI":"10.1016\/j.neurot.2024.e00446"},{"key":"6669_CR80","unstructured":"Manganelli, F., & Ruggiero, L. (2013, October 1). Clinical features of Pompe disease. PubMed Central (PMC). https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3866902\/"},{"issue":"12","key":"6669_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012993.pub2","volume":"12","author":"S Dalmia","year":"2023","unstructured":"Dalmia S, Sharma R, Ramaswami U, Hughes D, Jahnke N, Cole D, Smith S, Remmington T (2023) Enzyme replacement therapy for late-onset Pompe disease. Cochrane Database Syst Rev 12(12):CD012993. https:\/\/doi.org\/10.1002\/14651858.CD012993.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"6669_CR82","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/j.1468-1331.2010.02959.x","volume":"17","author":"S Ravaglia","year":"2010","unstructured":"Ravaglia S, Danesino C, Moglia A, Costa A, Cena H, Maccarini L, Carlucci A, Pichiecchio A, Bini P, De Filippi P, Rossi M (2010) Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis. Eur J Neurol 17(7):957\u2013962. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.02959.x","journal-title":"Eur J Neurol"},{"issue":"12","key":"6669_CR83","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/HUMU.21121","volume":"30","author":"JJ Flanagan","year":"2009","unstructured":"Flanagan JJ, Rossi B, Tang K et al (2009) The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat 30(12):1683\u20131692. https:\/\/doi.org\/10.1002\/HUMU.21121","journal-title":"Hum Mutat"},{"issue":"12","key":"6669_CR84","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ et al (2021) Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol 20(12):1027\u20131037. https:\/\/doi.org\/10.1016\/S1474-4422(21)00331-8","journal-title":"Lancet Neurol"},{"key":"6669_CR85","doi-asserted-by":"publisher","unstructured":"V H DO, Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Annals of Translational Medicine. 2019 Jul 1;7(13):291. https:\/\/doi.org\/10.21037\/atm.2019.04.15","DOI":"10.21037\/atm.2019.04.15"},{"key":"6669_CR86","doi-asserted-by":"crossref","unstructured":"Ashe KM, Taylor KM, Chu Q, Meyers E, Ellis A, Jingozyan V, et al. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. Mol Genet Metab [Internet]. 2010 Aug;100(4):309\u201315. Available from: http:\/\/refhub.elsevier.com\/S1096-7192(24)00474-8\/rf0580","DOI":"10.1016\/j.ymgme.2010.05.001"},{"key":"6669_CR87","doi-asserted-by":"publisher","unstructured":"Ullman JC, Mellem KT, Xi Y, Ramanan V, Merritt H, Choy R, et al. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. Sci Transl Med [Internet]. 2024 Jan 17;16(730). Available from: https:\/\/www.science.org\/doi\/https:\/\/doi.org\/10.1126\/scitranslmed.adf1691","DOI":"10.1126\/scitranslmed.adf1691"},{"key":"6669_CR88","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/mt.2009.37","volume":"17","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Jiang J-L, Gumlaw NK, Zhang J, Bercury SD, Ziegler RJ, Lee K, Kudo M, Canfield WM, Edmunds T et al (2009) Glycoengineered acid \u03b1-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe Disease. Mol Ther 17:954\u2013963","journal-title":"Mol Ther"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06669-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06669-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06669-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T02:31:23Z","timestamp":1770258683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06669-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6669"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06669-6","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}